Abstract:Malaria infections are common occurrences and one of the leading causes of death in developing countries. The World Health Organization reported 212 million malaria cases worldwide in 2016 which resulted in 429,000 deaths. The most affected group of individuals were children under the age of five which accounted for 70% of this death rate. There are no available vaccines for malaria, but the development of this type of treatment would provide a more cost‐effective and efficient way of battling this disease. Within populations affected by malaria, certain children and adolescents have developed protective immune responses against this disease. These protective immune responses decrease the intensity of the infection thus making the individual more resistant against the acquired disease. Through differential screening experiments, malarial‐protein antigens recognized by antibodies from resistant, but not susceptible individuals were discovered. The Plasmodium falciparum Glutamic Acid‐Rich Protein (PfGARP), an antigen that arrests the development of the parasite in its trophozoite stage was discovered using this method. The specific aim of this study was to express functional PfGARP in order to purify and characterize it as a vaccine candidate. The PfGARP gene was inserted into a plasmid vector that was then used to transform the expression system organism: Pichia pastoris. Individual colonies of recombinant P. pastoris were transferred from agar plates to liquid medium cultures. These were then analyzed for protein expression via Western blot every 24 hours after induction of protein expression. 94 colonies of recombinant P. pastoris were analyzed using this method and none showed expression of PfGARP. PCR analyses were then performed to determine the presence of the PfGARP gene in transformed P. pastoris. A set of vector‐specific primers was designed to amplify a region of 2242 base pairs which included the PfGARP gene in the middle of the region. Amplifications from DNA extracted from the recombinant cells showed a band size of roughly 1000 base pairs. Based on results from the Western blot and PCR analyses performed, it can be concluded that P. pastoris deletes a significant amount of the PfGARP gene's sequence and therefore is not a viable protein expression system for PfGARP. Support or Funding Information Research reported in this publication was supported by the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number T34GM008419. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Fusion of Two Malaria Vaccine Candidate Antigens Enhances Product Yield, Immunogenicity, and Antibody-Mediated Inhibition of Parasite Growth in Vitro

Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria

Blood-Stage Vaccine Candidate of Plasmodium Falciparum

Design and Evaluation of Chimeric Plasmodium falciparum Circumsporozoite Protein-Based Malaria Vaccines

Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.

Isolation and light chain shuffling of a Plasmodium falciparum AMA1-specific human monoclonal antibody with growth inhibitory activity

[Preparation and Characterization of Monoclonal Antibody Specific to PfCP-2.9 Chimeric Protein of Plasmodium Falciparum].

Production and Modification of Human Monoclonal Antibody Fab Fragments to the 19-Kilodalton C-Terminal Merozoite Surface Protein 1 of Plasmodium Falciparum

The molecular basis for peptide-based antimalarial vaccine development targeting erythrocyte invasion by P. falciparum

Leveraging Immunofocusing and Virus-like Particle Display to Enhance Antibody Responses to the Malaria Blood-Stage Invasion Complex Antigen PfCyRPA

Rice‐produced MSP142 of Plasmodium Falciparum Elicits Antibodies That Inhibit Parasite Growth in Vitro

Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein

Expression of Plasmodium falciparum Glutamic Acid‐Rich Protein (PfGARP) in Recombinant Pichia pastoris for Malaria Vaccine Development

Cd loop fusion enhances the immunogenicity and the potential transmission blocking activity of Plasmodium falciparum generative cell specific 1 (GCS1) antigen

Construction of a Vaccinia Virus Vectored Multi-Epitope Vaccine Candidate for Plasmodium Falciparum

Effects of vector fusion peptides on the conformation and immune reactivity of epitope-shuffled, recombinant multi-epitope antigens.

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity

Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein of Plasmodium vivax in murine model

A Self-Assembling Pfs230D1-Ferritin Nanoparticle Vaccine Has Potent and Durable Malaria Transmission-Reducing Activity

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Immature dendritic cell-targeting mRNA vaccine expressing PfCSP enhances protective immune responses against Plasmodium liver infection